Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans
- 1 January 2000
- journal article
- review article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 17 (11) , 1335-1344
- https://doi.org/10.1023/a:1007574217260
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Simulation of Clinical TrialsAnnual Review of Pharmacology and Toxicology, 2000
- ECONOMETRICS IN OUTCOMES RESEARCH: The Use of Instrumental VariablesAnnual Review of Public Health, 1998
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.Journal of Clinical Oncology, 1998
- An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug DevelopmentClinical Pharmacokinetics, 1997
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra-Short-Acting OpioidAnesthesia & Analgesia, 1993
- The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male VolunteersAnesthesiology, 1993
- Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentClinical Pharmacology & Therapeutics, 1992
- Pharmacokinetics, Pharmacodynamics, and Rational Opioid SelectionAnesthesiology, 1991
- Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug DevelopmentJNCI Journal of the National Cancer Institute, 1990